Reactions caused by photosensitivity, also called photodermatosis, are cutaneous reactions induced or exacerbated by exposure to electromagnetic radiation, including UV radiation, visible light, and infrared radiation. We present the case of a 41-year-old man with no personal history of allergy and who is referred to our Drug Allergy Unit for study. We performed a conventional patch test (non-irradiated) and photopatch (with the application of UVA) with reading at 48 and 96 hours and 24 hours after irradiation with an intensity of 5J/cm2. Drug-induced photosensitivity can manifest itself in two clinically indistinguishable forms: photoallergy and phototoxicity. Photoallergic reactions are due to an immunological response of type IV hypersensitivity (a cell-mediated mechanism). We present a case of photoallergy due to sensitization to naproxen, confirmed by photopatch tests.
Background: Rituximab is a chimeric murine/human monoclonal antibody against CD20. It can be used off label in autoimmune diseases. Its administration can lead to several types of reactions; infusional immediate reactions and also delayed reactions like Serum Sickness Reaction (SSR). Case presentation: 48 years old woman diagnosed with rheumatoid arthritis/systemic lupus erythematosus who developed refractory immune thrombocytopenic purpura and received treatment with rituximab. After treatment, she developed erythematous-violet lesions accompanied with fever of 38ºC, dyspnea, joints arthralgia and edema. In the Emergency Department they observed hypotension, fever, dyspnea, shivering, so intramuscular epinephrine, intravenous corticosteroids, antibiotics and salbutamol nebulization’s were administered. In our Allergy Unit we performed intradermal test (IDT) with rituximab (1mg/ml), which was positive at immediate (20min) and late (48h) reading. Attending to the clinical manifestations and test carried out, she was diagnosed with rituximab SSR. We also studied the molecular mass of the IgEreactive proteins present in rituximab product by SDS-PAGE Immunoblotting method according to Laemmli, in reducing and non-reducing conditions, with high sensitivity and using three different polyvinylidene difluoride (PVDF) membrane blocking substances (skimmed cow's milk, fish collagen and egg white). We did not detect IgE-binding to rituximab product. Conclusion: Pathogenesis of SSR is not well known. The patients after reinfusion can develop immediate reaction suggesting involved IgE hypersensitivity nevertheless there are patients who tolerated reinfusion. Further studies and assays are needed to bring greater understanding of this reactions and lead to a safer re-administration if needed.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.